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R. Milner *
University of Chicago Medical Center, Chicago, IL, USAInfected prosthesis in any vascular bed can be very challenging
to treat. Treating surgeons will usually attempt to ﬁnd any
technique that can be of lower risk to the patient and does not
require removal of the infected graft. Graft infection can be
especiallydifﬁcult to treatwhen the infectionoccurs in anypart
of the aorta. As our treatment paradigms continue to progress
tominimally invasive wire and catheter-based approaches, we
have become less interested in “big” operations that pose a
high risk for our patients. In light of this fact, I applaud the
authors for accumulating and analyzing their data associated
with the care of patients with infected aortic endografts.
Lyons et al.1 present the evaluation of a large series from
the UK. They were able to identify and analyze 22 patients
over a 14-year period who developed aortic graft infections
in the setting of an endovascular device. All of these pa-
tients were treated with a variety of modalities that
included less invasive management techniques for some
and explant with vascular reconstruction in others. The less
invasive management included endograft extension, as well
as drainage of the sac and antibiotic irrigation in some
patients. In addition, their series included patients treated
for thoracic and aortic aneurysmal disease.
Their results are very impressive tome in terms of the need
for being aggressive as an initial treatment for the infection.
None of the nine infected thoracic endograft patients un-
derwent an explant. At 24 months, eight of the nine patients
had not survived. This high mortality rate occurred as some
patients refused additional treatment for the infection or
were deemed too high risk. But, several had an attempt at an
endovascular solution with extensions, which did not lead to
survival as they all had disease progression and bleeding.* University of Chicago Medical Center, 5841 S. Maryland Avenue, MC
5028, Chicago, IL 60610, USA.
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http://dx.doi.org/10.1016/j.ejvs.2013.06.001The same impressive data are seen in the abdominal
aorta. In fact, it is even more telling in that some of the
patients did have an explant procedure and have survived.
Of the 13 infected aortic endograft patients, ten were
deemed appropriate risk for surgical removal of the device
and reconstruction. One patient died in the peri-operative
period and two other patients died during follow-up, but
seven (70%) survived. This survival rate is a dramatic
improvement compared with the thoracic patients who did
not have an explant. Also, infected abdominal aortic pa-
tients who did not have an explant did not survive. Mini-
mally invasive approaches, such as sac drainage, only led to
temporary control of sepsis and patients suffered with
disease progression and death.
I think the authors have done a great job in presenting
some very important and interesting data. Many of us,
including myself, strive to devise approaches to minimize
our patients’ operative risks. However, I am not willing to
accept such a high mortality rate for less invasive therapies.
In light of this, I would deﬁnitely change my treatment
paradigm the next time I treat a patient with an infected
aortic endograft. As long as the patient does not have a
prohibitive operative risk, I think that the outcome is clearly
improved with a more aggressive approach. Explant and
extra-anatomic reconstruction did much better in the cur-
rent series.
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